Clinical Trial Update: Study of Efficacy and Safety of Canakinumab in Japanese Patients With SJIA [Phase 3]

View source ↗

Summary

Phase 3 trial update on canakinumab for systemic juvenile idiopathic arthritis in Japanese patients; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Juvenile Idiopathic Arthritis

Drugs mentioned

• Canakinumab (canakinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Systemic Juvenile Idiopathic Arthritis | Phase 3 | Status: COMPLETED | Results posted: 2019-09-13